References
- Ahuja HG, Foti A, Bar-Eli M, Cline MJ (1990). The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood, 75, 1684-90.
- Bain BG, Clark DM, Wilkins BS (2010). Myeloprolifrative and myelodysplastic/Myeloprolifrative neoplasms and related conditions. In: Bain BG, Clark DM, Wilkins BS, editors. Bone marrrow pathology. 4th ed: Wiley-Blackwell, 240-2.
- Baum KJ, Ren R (2008). Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol, 1, 5. https://doi.org/10.1186/1756-8722-1-5
- Braun BS, Shannon K (2008). Targeting Ras in myeloid leukemias. Clin Cancer Res, 14, 2249-52. https://doi.org/10.1158/1078-0432.CCR-07-1005
- Braun BS, Tuveson DA, Kong N, et al (2004). Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA, 101, 597-602. https://doi.org/10.1073/pnas.0307203101
- Chan IT, Kutok JL, Williams IR, et al (2004). Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest, 113, 528-38. https://doi.org/10.1172/JCI20476
- LeMaistre A, Lee MS, Talpaz M, et al (1989). Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood, 73, 889-91.
- Liang DC, Shih LY, Fu JF, et al (2006). K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer, 106, 950-6. https://doi.org/10.1002/cncr.21687
- Mansi L, Viel E, Curtit E, Medioni J, Le Tourneau C (2011). Targeting the RAS signalling pathway in cancer. Bulletin Du Cancer, 98, 1019-28.
- McCubrey JA, Steelman LS, Abrams SL, et al (2008). Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia, 22, 708-22. https://doi.org/10.1038/leu.2008.27
- Nagasaka T, Sasamoto H, Notohara K, et al (2004). Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol, 22, 4584-94. https://doi.org/10.1200/JCO.2004.02.154
- Needleman SW, Gutheil JC, Kapil V, Mane SM (1989). Infrequent ras activation in chronic myelogenous leukemia (CML): Activating 61st codon mutation in the CML-derived cell line, IM-9. Leukemia, 3, 827-9.
- Pavlu J, Andreasson C, Chuah C, et al (2007). Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission. Bri J Haematol, 137, 423-8. https://doi.org/10.1111/j.1365-2141.2007.06578.x
- Preston R, Dabritz J, Hanfler J, Oettle H (2010). Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemia. Leukemia Res, 34, 883-91. https://doi.org/10.1016/j.leukres.2010.02.023
- Sano H, Shimada A, Taki T, et al (2012). RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese childhood AML cooperative study group. Int J Hematol, 95, 509-15. https://doi.org/10.1007/s12185-012-1033-x
- Serra A, Guerrasio A, Gaidano G, et al (1993). molecular defects associated with the acute-phase CML. Leukemia Lymphoma, 11, 25-8.
- Steelman LS, Franklin RA, Abrams SL, et al (2011). Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia, 25, 1080-94. https://doi.org/10.1038/leu.2011.66
- Stoppa G, Rumiato E, Saggioro D. (2012) Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells. Apoptosis, 17, 219-28. https://doi.org/10.1007/s10495-011-0676-z
- Stricker TP, Kumar V (2012). In: Kumar V, Abbas AK, Fausto N, Aster JC, editors (2012). Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia: Saunders Elsevier, 259-320.
- Tyner JW, Erickson H, Deininger MW, et al (2009). High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood, 113, 1749-55. https://doi.org/10.1182/blood-2008-04-152157
- Watzinger F, Gaiger A, Karlic H, et al (1994). Absence of n-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid-leukemia. Cancer Res, 54, 3934-8.
- Zhu X, Li Y, Luo X, Fei J (2012). Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells. Cellular Signalling, 24, 1134-40. https://doi.org/10.1016/j.cellsig.2012.01.016
Cited by
- Elevated Serum Ferritin Levels in Patients with Hematologic Malignancies vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6099
- High Frequency of Codon 12 but not Codon 13 and 61 K-ras Gene Mutations in Invasive Ductal Carcinoma of Breast in a South Indian Population vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3505